Cargando…
Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy
In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals. Defensins are the forgotten molecules that enhance the innate immunity against various microbes. Although macrolides like azithromycin and clarithromycin etc., have been reported to act against...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286248/ https://www.ncbi.nlm.nih.gov/pubmed/32554149 http://dx.doi.org/10.1016/j.mehy.2020.109984 |
_version_ | 1783544841784786944 |
---|---|
author | Chalichem, Nehru Sai Suresh Bethapudi, Bharathi Mundkinajeddu, Deepak |
author_facet | Chalichem, Nehru Sai Suresh Bethapudi, Bharathi Mundkinajeddu, Deepak |
author_sort | Chalichem, Nehru Sai Suresh |
collection | PubMed |
description | In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals. Defensins are the forgotten molecules that enhance the innate immunity against various microbes. Although macrolides like azithromycin and clarithromycin etc., have been reported to act against respiratory infections but they lack the ability of immunity enhancement through defensins. The aminoglycosides were proved to have defensin mediated antiviral activity, that could enhance the immunity. So, Consideration of aminoglycosides can be a double edge sword viz., against respiratory infection as well as Immunity enhancer (along with anti-virals) for COVID-19 regimen. |
format | Online Article Text |
id | pubmed-7286248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72862482020-06-11 Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy Chalichem, Nehru Sai Suresh Bethapudi, Bharathi Mundkinajeddu, Deepak Med Hypotheses Article In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals. Defensins are the forgotten molecules that enhance the innate immunity against various microbes. Although macrolides like azithromycin and clarithromycin etc., have been reported to act against respiratory infections but they lack the ability of immunity enhancement through defensins. The aminoglycosides were proved to have defensin mediated antiviral activity, that could enhance the immunity. So, Consideration of aminoglycosides can be a double edge sword viz., against respiratory infection as well as Immunity enhancer (along with anti-virals) for COVID-19 regimen. Elsevier Ltd. 2020-11 2020-06-10 /pmc/articles/PMC7286248/ /pubmed/32554149 http://dx.doi.org/10.1016/j.mehy.2020.109984 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chalichem, Nehru Sai Suresh Bethapudi, Bharathi Mundkinajeddu, Deepak Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title | Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title_full | Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title_fullStr | Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title_full_unstemmed | Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title_short | Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy |
title_sort | aminoglycosides can be a better choice over macrolides in covid-19 regimen: plausible mechanism for repurposing strategy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286248/ https://www.ncbi.nlm.nih.gov/pubmed/32554149 http://dx.doi.org/10.1016/j.mehy.2020.109984 |
work_keys_str_mv | AT chalichemnehrusaisuresh aminoglycosidescanbeabetterchoiceovermacrolidesincovid19regimenplausiblemechanismforrepurposingstrategy AT bethapudibharathi aminoglycosidescanbeabetterchoiceovermacrolidesincovid19regimenplausiblemechanismforrepurposingstrategy AT mundkinajeddudeepak aminoglycosidescanbeabetterchoiceovermacrolidesincovid19regimenplausiblemechanismforrepurposingstrategy |